Dodekin is a fully-human immunostimulatory product consisting of a vascular targeting antibody fused to the human cytokine interleukin-12 (IL12).

Recombinant IL12 has potent anti-cancer activity, but its therapeutic use is limited by associated toxicities. However, the site-selective delivery of IL12 to the sub-endothelial extracellular matrix in tumor blood vessels allows to drastically improve the therapeutic index of this cytokine.

Quantitative biodistribution studies of Dodekin have shown a preferential uptake of the molecule in tumor tissues compared to healthy organs. Preclinical studies in several immunocompetent murine models of cancer have shown that this immunocytokine has a potent anti-tumor activity and is able to induce long-lasting tumor eradication. It further potentiates the action of other therapeutic agents such as immunological checkpoint inhibitors.

In a recently established collaboration with the University Hospital Zurich, the murine surrogate of Dodekin has demonstrated a striking single-agent anti-cancer activity in preclinical models bearing orthotopic glioblastoma. The treatment induced long-term tumor eradications in a substantial proportion of the treated animals.


  • A phase I study to evaluate safety and early signs of efficacy of Dodekin in patients with advanced solid carcinomas and DLBCL after previous immune-checkpoint blockade therapy (NCT04471987).



Weiss et al., (2020) Sci Transl Med, 12 (564):eabb2311
Puca et al. (2020) Int J Cancer, 146, 2518-30
Hutmacher et al. (2019) Cancer Immune Res, 7, 572-83
Ongaro et al. (2019) J Biotechnol, 291, 17-25
Mosely et al. (2017) Cancer Immunol Res, 5, 29-41
Hemmerle & Neri (2014) Int J Cancer, 134, 467-77
Lasek et al. (2014) Cancer Immunol Immunother, 63, 419-35
Pasche et al. (2012) Clin Cancer Res, 12, 4092-103
Sommavilla et al. (2010) Protein Engin Des Sel, 23, 653-61
Gafner et al. (2006) Int J Cancer, 119, 2205-12
Halin et al. (2003) Cancer Res, 63, 3202-10
Halin et al. (2002) Nat Biotechnol, 20, 264-9
Castellani et al. (2002) Am . Pathol, 161, 1695-1700


By continuing to browse or by closing this window, you accept the use of cookies.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. By closing this banner or continuing to browse, you agree to the use of cookies.

I Accept Cookie Policy